Abstract
Determination of HER2 protein expression by immunohistochemistry (IHC) and genomic status by fluorescent in situ hybridisation (FISH) are important in identifying a subset of high HER2-expressing gastric cancers that might respond to trastuzumab. Although FISH is considered the standard for determination of HER2 genomic status, brightfield ISH is being increasingly recognised as a viable alternative. Also, the impact of HER2 protein expression/genomic heterogeneity on the accuracy of HER2 testing has not been well studied in the context of gastric biopsy samples.
| Original language | English |
|---|---|
| Pages (from-to) | 880-3 |
| Number of pages | 4 |
| Journal | Journal of Clinical Pathology |
| Volume | 64 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chromosomes, Human, Pair 17
- Receptor, erbB-2
- Chi-Square Distribution
- Humans
- In Situ Hybridization, Fluorescence
- Biopsy
- Predictive Value of Tests
- Gene Amplification
- False Negative Reactions
- In Situ Hybridization
- Stomach Neoplasms
- Singapore
- Tumor Markers, Biological
- Immunohistochemistry
Fingerprint
Dive into the research topics of 'Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver